Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations
暂无分享,去创建一个
G. Minuti | L. Crinò | M. Canale | E. Petracci | A. Delmonte | M. Mariotti | V. Ludovini | P. Ulivi | A. Dubini | G. Metro | S. Baglivo | M. Puccetti | P. Cravero | Giovanni Martinelli
[1] Jae Cheol Lee,et al. Contribution of p53 in sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer , 2021, Scientific Reports.
[2] S. Ou,et al. Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC. , 2021, Lung cancer.
[3] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[4] Y. Ohe,et al. Proteasome Inhibition Overcomes ALK-TKI Resistance in ALK-Rearranged/TP53-Mutant NSCLC via Noxa Expression , 2020, Clinical Cancer Research.
[5] A. Neri,et al. Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter? , 2020, Frontiers in Oncology.
[6] M. Ahn,et al. Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L. , 2020 .
[7] Anna L. Brown,et al. Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer , 2020, Cell reports medicine.
[8] L. Landi,et al. Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs , 2020, Journal of clinical medicine.
[9] H. Hou,et al. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis , 2019, BMC Cancer.
[10] Olaf Neumann,et al. Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases , 2019, International journal of cancer.
[11] C. Couture,et al. Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes , 2019, Molecular Cancer Therapeutics.
[12] A. Stenzinger,et al. Defining molecular risk in ALK+ NSCLC , 2019, Oncotarget.
[13] L. Moens,et al. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11. , 2019, Lung cancer.
[14] Fanshuang Zhang,et al. Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK‐rearranged non‐small‐cell lung cancer , 2019, Cancer medicine.
[15] Jiamei Li,et al. Prognostic value of KRAS/TP53/PIK3CA in non-small cell lung cancer , 2019, Oncology letters.
[16] J. Ahn,et al. Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR‐Mutated Advanced NSCLC , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[17] P. Schirmacher,et al. Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival , 2019, Cancers.
[18] C. Gridelli,et al. Brigatinib versus Crizotinib in ALK‐Positive Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.
[19] F. Ciardiello,et al. Role and targeting of anaplastic lymphoma kinase in cancer , 2018, Molecular Cancer.
[20] Jon R. Armstrong,et al. Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer , 2018, Modern Pathology.
[21] Wei Wu,et al. Non-Canonical Thinking for Targeting ALK-Fusion Onco-Proteins in Lung Cancer , 2017, Cancers.
[22] X. Yi,et al. TP53 mutations predict for poor survival in ALK rearrangement lung adenocarcinoma patients treated with crizotinib. , 2018, Journal of thoracic disease.
[23] M. Tsao,et al. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC). , 2017, Lung cancer.
[24] Rafal Dziadziuszko,et al. Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[25] Nicolai J. Birkbak,et al. Tracking the Evolution of Non‐Small‐Cell Lung Cancer , 2017, The New England journal of medicine.
[26] A. Shaw,et al. Targeting ALK: Precision Medicine Takes on Drug Resistance. , 2017, Cancer discovery.
[27] Jeffrey N Myers,et al. TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response , 2016, Journal of cellular biochemistry.
[28] T. Clackson,et al. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial. , 2016, The Lancet. Oncology.
[29] Weijun Ou,et al. TP53 mutation is associated with a poor clinical outcome for non-small cell lung cancer: Evidence from a meta-analysis , 2016, Molecular and clinical oncology.
[30] Michael Thomas,et al. Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer (NSCLC): updated results from the phase 1, multicentre, open-label ASCEND-1 trial , 2016, The Lancet. Oncology.
[31] R. Govindan,et al. Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] V. Mittal,et al. Novel ALK inhibitors in clinical use and development , 2015, Journal of Hematology & Oncology.
[33] Hyojin Kim,et al. Overview of clinicopathologic features of ALK-rearranged lung adenocarcinoma and current diagnostic testing for ALK rearrangement. , 2015, Translational lung cancer research.
[34] F. Cappuzzo,et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. , 2014, The New England journal of medicine.
[35] R. Govindan,et al. TP53 Mutations and Lung Cancer: Not All Mutations Are Created Equal , 2014, Clinical Cancer Research.
[36] Steven J. M. Jones,et al. Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.
[37] William Pao,et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. , 2014, JAMA.
[38] Jianmin Wu,et al. Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling , 2014, Cell.
[39] S. Gabriel,et al. Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.
[40] F. Végran,et al. Only Missense Mutations Affecting the DNA Binding Domain of P53 Influence Outcomes in Patients with Breast Carcinoma , 2013, PloS one.
[41] Ming K. Lee,et al. Cell-type, dose, and mutation-type specificity dictate mutant p53 functions in vivo. , 2012, Cancer cell.
[42] A. Wellstein,et al. Hunting ALK to feed targeted cancer therapy , 2011, Nature Medicine.
[43] Jeffrey W. Clark,et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.
[44] Shinji Yamazaki,et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. , 2007, Cancer research.
[45] T. Jacks,et al. Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.
[46] Anindita Das,et al. Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes , 2004, Oncogene.
[47] L. Donehower,et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.
[48] Xue Wu,et al. Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer. , 2019, Lung cancer.
[49] D. Lane,et al. Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others , 2018, Nature Reviews Clinical Oncology.
[50] M. Visker,et al. Cell-Type - , 2017 .
[51] J. Engelman,et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. , 2014, The New England journal of medicine.
[52] R. Rosell,et al. Nondisruptive p 53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non – Small Cell Lung Cancer , 2014 .
[53] M. Scian,et al. Tumor-derived p53 mutants induce NF-kappaB2 gene expression. , 2005, Molecular and cellular biology.